While there have been exciting advancements in the treatment of B-cell acute lymphoblastic leukemia over the course of the past decade, the treatment of older adults remains a challenge.
Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.
Janet L. Abrahm, MD, FACP, FAAHPM, discussed the high rates of oncologist burnout and compassion fatigue.
For Breast Cancer Awareness Month, Deborah Toppmeyer, MD, emphasizes the crucial role of early breast cancer detection.
Sham Mailankody, MBBS, looks to the future treatment landscape for early relapsed/refractory multiple myeloma and addresses ways to improve patient access to care.
Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.
Tremendous strides in science have led to a wave of precision medicine-based approaches for patients that consider each patient’s underlying genetics and what makes each patient’s cancer unique.
Adaptation of improved methods of MRD detection are needed to better define this population at risk.
Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.
Ariel Perez, MD, discusses polatuzumab vedotin in combination with bendamustine and rituximab since garnering approval from the FDA and studies that evaluated the combination.
Gene G. Finley, MD, provides advice to community oncologists who are treating patients with small cell lung cancer.
Panelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.
Results from a study evaluating circulating tumor tissue–modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma is of interest.
Matthew Hadfield, DO, discusses what community oncologists should know about immunotherapy toxicities.
Ashley Yocum, PhD, discusses the Beat AML trial of biomarker-based treatments in acute myeloid leukemia.
Select racial groups have benefitted from important updates made to the USPSTF lung cancer screening guideline a year ago.
Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.
Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Paul Lammers, MD, MSc, talks about the future of cell therapies and the applications of TAC-01 in solid tumors.
Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant cyclophosphamide-based hematopoietic cell transplantation.
The panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Technology plays a pivotal role in enhancing precision medicine within cancer care.
Jia Ruan, MD, PhD, discusses the results of the multicenter phase 2 trial of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in patients with peripheral T-cell lymphoma.
Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.
Anne Wooford, MD, provides background on her presentation around allogeneic stem cell transplant for the 2022 Transplantation & Cellular Therapy Meetings.